BGPT: Author Review: Madeleine Petersson Sjögren

Fuel Your Discoveries

Quick Explanation Copied

Author scientific profile (evidence-backed from listed works)

Madeleine Petersson Sjögren’s visible publication record clusters around lung/respiratory measurement methods (notably AiDA) and respiratory biomarkers, with additional work in atmospheric/biological aerosol measurements. Examples include AiDA validation/benchmarking in humans (), AiDA comparisons to conventional lung function tests (), and population-based emphysema-related measurement work in SCAPIS (). Her record also includes environmental bioaerosol measurement reporting ().

Overall scientific signal: method-development/validation orientation with moderate evidence strength per provided item, but the public metadata provided here does not let us judge full rigor details (e.g., blinding, calibration protocols, causal inference) without full texts.

Long Explanation

Author Review: Madeleine Petersson Sjögren

Evidence basis here is limited to the works and metadata explicitly provided (OpenAlex-derived listing + DOIs/abstract metadata). Where full methods/results aren’t available in the prompt, I mark uncertainty.

1) What this author appears to work on (from listed works)

Respiratory measurement innovation and translation centered on AiDA (Airspace Dimension Assessment) using inhaled nanoparticles, including benchmarking against imaging and comparison to conventional lung-function testing (; ).
Clinical/epidemiologic association efforts linking AiDA parameters with emphysema-related traits in a population-based cohort (SCAPIS) ().
Extension to occupational/environmental lung health contexts (e.g., welders; firefighters) emphasizing detection when standard spirometry may miss changes (; ).
Additional domain signal in measurement of biological aerosols in the atmosphere (fluorescent bioaerosol concentrations in a coniferous forest) ().

2) Evidence visualization: relative community attention (citations)

Using the cited-by counts provided in the prompt metadata for the listed top works. This is a proxy for attention, not proof of quality.

How to interpret this chart skeptically

Citation counts are influenced by visibility, field size, and topic trends—so they cannot substitute for rigor assessment.
To judge rigor, we would need full methods (e.g., calibration, measurement error models, blinding, missingness handling) and independent replication. The prompt here doesn’t include those details.

3) Scientific strengths (grounded in the listed items)

3.1 Measurement innovation with explicit benchmarking/comparators

The AiDA line appears to repeatedly anchor claims to comparative reference measurements—e.g., benchmarking against hyperpolarised 129Xe diffusion-weighted lung MRI (). This is a good evidentiary strategy when proposing new measurement modalities.

3.2 Application-oriented validation: beyond “can it measure”, toward “does it add information”

The comparison to established pulmonary function testing () and population-based emphysema biomarker framing () suggest translational ambition.

3.3 Multi-domain measurement literacy

The atmospheric fluorescent bioaerosol report indicates capability in long-duration environmental measurement reporting (). This kind of work can strengthen general experimental rigor (though domain transfer is not guaranteed).

4) Scientific rigor gaps & skepticism checkpoints (what we cannot verify from the provided prompt)

Measurement error model transparency: AiDA claims rely on nanoparticle inhalation, imaging/processing, and geometric/graph-based derivations. The prompt doesn’t include whether uncertainty propagation is modeled, how reproducibility is tested, or how confounders (e.g., ventilation heterogeneity, breathing patterns) are handled.
Clinical inference vs correlation: SCAPIS-based biomarker framing () may be susceptible to residual confounding and overfitting if model validation strategy is not robust. Full text needed.
External validity: occupational-context studies (welders/firefighters) (; ) may not generalize across exposure types, equipment, scanner settings, or protocol versions.
Selection and reporting bias: the prompt lists several works but not sample sizes, inclusion criteria, attrition, or full reporting behavior (e.g., pre-registration, analysis plan). Without that, we cannot judge susceptibility to selective reporting.
Replication status: the prompt provides citation proxies but not replication attempts by independent groups; replication is particularly important for novel measurement technologies.

5) Structured evidence table (selected works with DOIs)

Year	Work	DOI	Claim type (from abstract metadata)	Evidence strength (based on metadata only)
2021	AiDA by inhaled nanoparticles: benchmarking with hyperpolarised 129Xe diffusion-weighted lung MRI	10.1038/s41598-021-83975-7	Benchmark/validity comparison vs imaging reference	Moderate (depends on full methods not provided)
2021	Airspace dimension assessment with nanoparticles as a proposed biomarker for emphysema	10.1136/thoraxjnl-2020-214523	Population cohort association/biomarker framing	Moderate (correlation vs causation needs full text)
2022	AiDA in comparison to established pulmonary function tests	10.2147/ijn.s360271	Incremental information vs conventional PFTs	Moderate (needs details on test robustness)
2023	Sensitive methods for assessment of lung health in welders and controls	10.1016/j.rmed.2023.107244	Sensitivity claim when spirometry is insufficient	Moderate (protocol/sample details unknown here)
2023	AiDA for early detection of lung function impairment in firefighters	10.1183/23120541.00504-2022	Early peripheral impairment detection claim	Moderate (needs full evaluation design)
2023	Atmospheric fluorescent bioaerosol concentrations measured during 18 months in a coniferous forest	10.5194/acp-23-4977-2023	Long-duration measurement report	Moderate (measurement design details not in prompt)

Note: The “evidence strength” column is my cautious rating based only on the abstract-level metadata provided in the prompt, not on full-text appraisal.

6) Bottom-line scientific assessment (confidence-tagged)

Known/observable from provided evidence: The listed works support a consistent theme of lung measurement development using AiDA with benchmarking/comparison strategies and application in relevant cohorts/occupational contexts (; ; ).
Uncertain because full-text methods are missing here: the degree to which measurement uncertainty, confounding, and external validity are handled rigorously. These factors can materially change confidence in the technology and biomarker claims.
Confidence level: Moderate that the author is productively involved in respiratory measurement/biomarker development; low-to-moderate that the specific claims are quantitatively robust without full methods and replication evidence.

What would most disprove or revise this assessment?

If full texts show weak benchmarking design (e.g., inadequate calibration, failure to model measurement error), or if independent replication fails to reproduce key measurement/bio-marker relationships ().
If the emphysema/biomarker claims are shown to collapse after controlling for key confounders or using holdout/independent validation ().
If occupational-context sensitivity claims are not reproducible across sites/exposures ().

Note on scope: This review does not assess the author’s entire oeuvre; it focuses on the explicitly provided, DOI-tagged works.

Feedback:

Updated: March 24, 2026